Los Angeles, California 90095

  • HIV Infections


To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis.


Inclusion Criteria Prior Medication: Allowed within 6 months of study entry: - Treatment for oral candidiasis. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Either history of esophageal candidiasis or current mucocutaneous candidiasis (angular cheilitis). - Allergies to chlorhexidine. - Gross periodontal neglect or need for periodontal treatment within the past two weeks. Concurrent Medication: Excluded: - Systemic or oral topical mucocutaneous antifungal therapy. - Systemic or oral topical corticosteroids. - Antibiotics. - Mouth rinses other than the study drug. Concurrent Treatment: Excluded: - Dental prophylaxis. Patients with the following are excluded: - Complete dentures, full partial dentures, removable dentures which fit poorly, or any prosthetic appliances which cannot be cleaned with sodium hypochlorite. - Allergies to chlorhexidine. - Sensitivity/intolerance to alcohol. - Anterior composite/acrylic restorations with poor marginal adaption. - Gross periodontal neglect or periodontal treatment within the past two weeks. - Inability to comply with the study protocol based on the investigator's discretion. Prior Medication: Excluded within 7 days of study entry: - Systemic or oral topical mucocutaneous antifungal therapy. - Antibiotics. - Daily use of mouth rinses. - Excluded within 1 month of study entry: - Systemic or oral topical corticosteroids. Prior Treatment: Excluded within 2 weeks of starting study drug: - Dental prophylaxis or periodontal treatment. Patients must be: - HIV positive. - Previously experienced at least one episode of clinically diagnosed oral candidiasis but currently free of clinical signs of oral candidiasis. - Willing to sign informed consent. - Willing to complete a medical history.

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

Official Title:

A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals

Overall Status:


Study Phase:




Minimum Age:

13 Years

Maximum Age:

75 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

NIH AIDS Clinical Trials Information Service

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Study Dates

Verification Date:November 1993
Last Changed Date:June 23, 2005
First Received Date:November 2, 1999

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Drug
Name:Chlorhexidine gluconate

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Procter and Gamble

Sample and Retention Information

There are no available Sample and Retention Information

Study References

Reference Type:Reference
Citation:Greenspan D. Treatment of oral candidiasis in HIV infection. Oral Surg Oral Med Oral Pathol. 1994 Aug;78(2):211-5. Review.

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.